Gurnet Point Capital and Novo Holdings have completed their acquisition of Paratek Pharmaceuticals in a deal valued at $462 million, according to a news release.
Paratek, founded in 1996 and based in Boston, is a commercial-stage biopharmaceutical company
Continue Reading Healthcare & Life Sciences Private Equity Deal Tracker: Gurnet Point and Novo Holdings Acquire Paratek Pharmaceuticals